Status:
UNKNOWN
Validating and Optimizing Model of Antipsychotics Selection
Lead Sponsor:
Shanghai Mental Health Center
Conditions:
Schizophrenia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This multi-centre study will evaluate the clinical efficacy of 3 atypical antipsychotics treatment in Chinese Patients with Schizophrenia by comparing model-decision with real-world psychiatrist-decis...
Eligibility Criteria
Inclusion
- An in-patient or out-patient (male or female) and aged ≥18 years
- A diagnosis of schizophrenia, DSM-5 (Diagnostic and Statistical Manual Diploma in Social Medicine-5)
- Subjects must have the ability to effectively communicate with investigator, complete study related documents, comprehend the key components of the consent form and must provide written informed consent to participate in the study prior to any study specific assessments or procedures.
- Patients are taking or will take atypical antipsychotics which include olanzapine, risperidone, aripiprazole.
- Baseline PANSS Total Score ≥70
Exclusion
- Participation in other clinical studies.
- Known intolerance or lack of efficacy to olanzapine, risperidone or aripiprazole.
- Use of clozapine within 28 days prior to randomization.
- Other conditions which, in the investigator's judgment, render patients unsuitable for the clinical study.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT03237052
Start Date
January 1 2018
End Date
December 1 2020
Last Update
August 9 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China, 200030